iRhythm Technologies delivered a strong third quarter in 2025, achieving record quarterly revenue of $192.9 million, a 30.7% increase year-over-year. The company also significantly reduced its net loss and adjusted net loss compared to the previous year, demonstrating improved operational efficiency and profitability. Gross margin expanded to 71.1%, and the company reported record free cash flow generation.

iRhythm Technologies delivered a strong second quarter in 2025, achieving record quarterly revenue of $186.7 million, a 26.1% increase year-over-year. The company also improved its gross margin to 71.2% and significantly reduced its net loss to $14.2 million, demonstrating strong operational execution and growth across its core monitoring business and new channel partners.

iRhythm Technologies reported strong first quarter 2025 financial results with revenue exceeding 20% growth year-over-year, driven by increased demand for Zio services and momentum in value-based care accounts. The company also expanded its global reach with the launch of Zio monitor in Japan.

iRhythm Technologies reported Q4 2024 revenue of $164.3 million, a 24% increase year-over-year. The company improved its gross margin to 70.0%, and net loss narrowed significantly to $1.3 million from $38.7 million in Q4 2023. Adjusted EBITDA rose to $19.3 million, reflecting strong demand for Zio services. Cash and cash equivalents increased to $535.6 million, supporting continued investments in growth and technology.

iRhythm Technologies reported a 19.3% increase in revenue for the second quarter of 2024, driven by strong demand for Zio services. The company is also progressing with European launches and anticipates a regulatory decision in Japan.

iRhythm Technologies reported revenue of $124.1 million, a 21.6% increase compared to the second quarter of 2022. The company's gross margin improved to 69.5%.

iRhythm Technologies reported a 20.6% increase in revenue to $111.4 million for the first quarter of 2023, driven by Zio XT and AT volume growth. The gross margin improved to 67.9%, and the company updated its fiscal year 2023 revenue guidance to a range of $480 million to $490 million.

iRhythm Technologies reported a 37.7% increase in revenue for the fourth quarter of 2022, reaching $112.6 million. The company's gross margin improved to 69.9%, and it achieved a net loss improvement of $12.3 million. Adjusted EBITDA was $1.1 million, marking an $18.4 million improvement.

iRhythm Technologies, Inc. reported a 21.6% increase in revenue to $103.9 million for the third quarter of 2022, compared to the same period in 2021. The company's gross margin improved to 68.3%, and cash, cash equivalents and short-term investments totaled $203.5 million as of September 30, 2022. However, the company is updating its fiscal year 2022 revenue guidance to a range of approximately $407 million to $411 million.

iRhythm Technologies reported a 25.6% increase in revenue to $102.1 million for the second quarter of 2022, driven by Zio XT and AT volume growth and increases in Medicare pricing. The company's gross margin improved to 68.8%.

iRhythm Technologies reported a 24.3% increase in revenue to $92.4 million for the first quarter of 2022. The company saw a gross margin of 66.9% and an adjusted EBITDA loss of $4.8 million. New account openings were up 15% quarter-over-quarter.

iRhythm Technologies reported a 3.8% increase in revenue for the fourth quarter of 2021, reaching $81.8 million. However, the company experienced a decline in gross margin to 62.7% and an adjusted EBITDA of negative $17.3 million. The company's cash and short-term investments amounted to $239.1 million at the end of the year.

iRhythm Technologies reported a revenue of $85.4 million for Q3 2021, an 18.7% increase compared to Q3 2020. The increase was driven by volume growth but was partially offset by a decrease in Zio XT Medicare reimbursement rates. Gross margin was 65.7%, down from 74.7% in the same period last year. The net loss for the quarter was $23.7 million, or $0.81 per share.

iRhythm Technologies reported a 59.8% increase in revenue to $81.3 million for the second quarter of 2021. The company's gross margin was 68.0%, and the adjusted EBITDA was negative $4.6 million. The company expects revenue to range from $320 million to $325 million for the full year 2021.

iRhythm Technologies reported a 17% increase in revenue to $74.3 million for the first quarter of 2021, driven by Zio XT volume and Zio AT expansion. However, the gross margin decreased to 68.4% due to reduced Medicare reimbursement rates and COVID-19 pandemic related costs. The company is actively pursuing multiple paths to achieve better reimbursement rates and focusing on efficiency improvements.

iRhythm Technologies announced strong fourth-quarter results, with a 33.3% increase in revenue compared to the same period in 2019. The company's revenue reached $78.8 million, driven by Zio XT volume and Zio AT expansion. However, the gross margin decreased by 2.5% due to costs related to Home Enrollment, higher shipping costs, and COVID-related expenses. The company is unable to provide revenue or margin guidance, and unable to provide full year OPEX guidance due to continuing uncertainties in reimbursement.

iRhythm Technologies reported a revenue increase of 31.6% to $71.9 million compared to the third quarter of 2019, and achieved a gross margin of 74.7%. Adjusted EBITDA was positive for the first time at $14.8 million. The company's cash and short-term investments totaled $327.2 million at quarter end.

iRhythm Technologies reported a slight decrease in revenue for the second quarter of 2020, with a 3% decrease compared to the same period in 2019. The decrease was primarily due to lower volumes but was slightly offset by increased ASP. The company experienced a net loss of $20.4 million, or $0.75 per share.

iRhythm Technologies reported a 31% increase in revenue to $63.5 million for the three months ended March 31, 2020, compared to $48.3 million in the same period in 2019. The gross margin was 74.7%, and the net loss was $9.1 million, or $0.34 per share.